Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9683779 | 0.94 | TSHR (0.56) | TSHRGABRA1GABRG2GABRB3GABRB2 | |
| Propane SCHEMBL27557470 | 0.87 | GABRA1 (0.48) | TSHRGABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL104314 | 0.84 | GABRA1 (0.55) | TSHRGABRA1GABRG2GABRB3GABRB2 | |
| Lithium SCHEMBL30421854 | 0.82 | GABRA1 (0.52) | TSHRGABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL30791052 | 0.82 | GABRA1 (0.52) | TSHRGABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL6692957 | 0.82 | GABRA1 (0.52) | TSHRGABRA1GABRG2GABRB3GABRB2 | |
| Hydrochloric Acid SCHEMBL8615487 | 0.82 | GABRA1 (0.52) | TSHRGABRA1GABRG2GABRB3GABRB2 | |
| Lithium Ion SCHEMBL29536467 | 0.82 | GABRA1 (0.52) | TSHRGABRA1GABRG2GABRB3GABRB2 | |
| Methane SCHEMBL27577653 | 0.82 | GABRA1 (0.52) | TSHRGABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL10798080 | 0.82 | TSHR (0.48) | TSHRHPGDLMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152651-B1 | THERAPEUTIC COMPOUNDS | PHARMACOFORE INC (US) | 2012-01-04 | — | — | EP | claimed |
| WO-2023122078-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20130217783-A1 | Therapeutic Compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217783-A1 | Therapeutic Compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217783-A1 | Therapeutic Compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8350097-B2 | Therapeutic compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350097-B2 | Therapeutic compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350097-B2 | Therapeutic compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120196939-A1 | Therapeutic Compounds | SOWOOD HEALTHCARE LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120196939-A1 | Therapeutic Compounds | SOWOOD HEALTHCARE LLC | 2012-08-02 | — | — | US | disclosed |
| EP-2152651-B1 | THERAPEUTIC COMPOUNDS | PHARMACOFORE INC (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2392559-A1 | Therapeutic compounds | Pharmacofore, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392559-A1 | Therapeutic compounds | Pharmacofore, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20100249246-A1 | Therapeutic Compounds | PHARMACOFORE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249246-A1 | Therapeutic Compounds | PHARMACOFORE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249246-A1 | Therapeutic Compounds | PHARMACOFORE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2152651-A1 | THERAPEUTIC COMPOUNDS | Pharmacofore, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008141099-A1 | THERAPEUTIC COMPOUNDS | PHARMACOFORE, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-4194008-A | INSECTICIDE, FUNGICIDE, MITICIDE, PARASITICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-03-18 | — | — | US | disclosed |
| EP-0000365-A1 | N-aryl-N'-alcoyl-S-alcoyl isothioureas, process for their preparation and their use against animal and vegetal pests | BAYER AG (DE) | 1979-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217783-A1 | Therapeutic Compounds | OPRM1, OGFR, UGT1A1 | TSHR 1530/4885GABRA1 202/4885GABRG2 593/4885 |
| US-20100249246-A1 | Therapeutic Compounds | OPRM1, OGFR, UGT1A1 | TSHR 1530/4885GABRA1 202/4885GABRG2 593/4885 |
| US-20120196939-A1 | Therapeutic Compounds | OPRM1, OPRD1, SCN1B | TSHR 1877/4885GABRA1 84/4885GABRG2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.